Suppr超能文献

澳大利亚太攀蛇(澳大拉西亚环蛇属)咬伤:早期抗蛇毒血清治疗的临床效果及潜在益处——澳大利亚蛇咬伤项目(ASP - 25)

Australian taipan (Oxyuranus spp.) envenoming: clinical effects and potential benefits of early antivenom therapy - Australian Snakebite Project (ASP-25).

作者信息

Johnston Christopher I, Ryan Nicole M, O'Leary Margaret A, Brown Simon G A, Isbister Geoffrey K

机构信息

a Clinical Toxicology Research Group, University of Newcastle , Newcastle , Australia.

b Centre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical Research, Royal Perth Hospital and the University of Western Australia , Perth , Australia.

出版信息

Clin Toxicol (Phila). 2017 Feb;55(2):115-122. doi: 10.1080/15563650.2016.1250903. Epub 2016 Nov 30.

Abstract

CONTEXT

Taipans (Oxyuranus spp.) are medically important venomous snakes from Australia and Papua New Guinea. The objective of this study was to describe taipan envenoming in Australian and its response to antivenom.

METHODS

Confirmed taipan bites were recruited from the Australian Snakebite Project. Data were collected prospectively on all snakebites, including patient demographics, bite circumstances, clinical effects, laboratory results, complications and treatment. Blood samples were taken and analysed by venom specific immunoassay to confirm snake species and measure venom concentration pre- and post-antivenom.

RESULTS

There were 40 confirmed taipan bites: median age 41 years (2-85 years), 34 were males and 21 were snake handlers. Systemic envenoming occurred in 33 patients with neurotoxicity (26), complete venom induced consumption coagulopathy (VICC) (16), partial VICC (15), acute kidney injury (13), myotoxicity (11) and thrombocytopenia (7). Venom allergy occurred in seven patients, three of which had no evidence of envenoming and one died. Antivenom was given to 34 patients with a median initial dose of one vial (range 1-4), and a median total dose of two vials (range 1-9). A greater total antivenom dose was associated with VICC, neurotoxicity and acute kidney injury. Early antivenom administration was associated with a decreased frequency of neurotoxicity, acute kidney injury, myotoxicity and intubation. There was a shorter median time to discharge of 51 h (19-432 h) in patients given antivenom <4 h post-bite, compared to 175 h (27-1104 h) in those given antivenom >4 h. Median peak venom concentration in 25 patients with systemic envenoming and a sample available was 8.4 ng/L (1-3212 ng/L). No venom was detected in post-antivenom samples, including 20 patients given one vial initially and five patients bitten by inland taipans.

DISCUSSION

Australian taipan envenoming is characterised by neurotoxicity, myotoxicity, coagulopathy, acute kidney injury and thrombocytopenia. One vial of antivenom binds all measurable venom and early antivenom was associated with a favourable outcome.

摘要

背景

太攀蛇(澳大拉西亚蛇属)是来自澳大利亚和巴布亚新几内亚的具有重要医学意义的毒蛇。本研究的目的是描述澳大利亚的太攀蛇咬伤情况及其对抗蛇毒血清的反应。

方法

从澳大利亚蛇咬伤项目中招募确诊的太攀蛇咬伤病例。前瞻性收集所有蛇咬伤的数据,包括患者人口统计学信息、咬伤情况、临床症状、实验室检查结果、并发症及治疗情况。采集血样并通过毒液特异性免疫测定进行分析,以确认蛇的种类并测量注射抗蛇毒血清前后的毒液浓度。

结果

共有40例确诊的太攀蛇咬伤病例:中位年龄41岁(2 - 85岁),男性34例,21例为捕蛇者。33例患者发生全身中毒,表现为神经毒性(26例)、完全性毒液诱导消耗性凝血病(VICC,16例)、部分VICC(15例)、急性肾损伤(13例)、肌毒性(11例)和血小板减少(7例)。7例患者发生毒液过敏,其中3例无中毒证据,1例死亡。34例患者接受了抗蛇毒血清治疗,初始中位剂量为1瓶(范围1 - 4瓶),总中位剂量为2瓶(范围1 - 9瓶)。抗蛇毒血清总剂量越大,与VICC、神经毒性和急性肾损伤相关。早期给予抗蛇毒血清与神经毒性、急性肾损伤、肌毒性和插管发生率降低相关。咬伤后<4小时接受抗蛇毒血清治疗的患者中位出院时间为51小时(19 - 432小时),而咬伤后>4小时接受治疗的患者中位出院时间为175小时(27 - 1104小时)。25例发生全身中毒且有血样的患者毒液浓度峰值中位数为8.4 ng/L(1 - 3212 ng/L)。抗蛇毒血清治疗后的样本中未检测到毒液,包括最初接受1瓶抗蛇毒血清治疗的20例患者和被内陆太攀蛇咬伤的5例患者。

讨论

澳大利亚太攀蛇咬伤的特征为神经毒性、肌毒性、凝血病、急性肾损伤和血小板减少。1瓶抗蛇毒血清可结合所有可测量的毒液,早期给予抗蛇毒血清与良好预后相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验